Zug, Switzerland, August 3, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its
financial results for the second quarter of 2017 on Thursday, August 10, 2017. Following the announcement, Auris Medical's
management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the
Company's financial results and to provide a general business update.
To participate in this conference call, dial 1-877-280-1254 (USA) or +1-212-444-0896 (International), and enter
passcode 1366409. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical
website at www.aurismedical.com. A replay will be available approximately two hours following the live
call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important
unmet medical needs in neurotology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing
loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with
biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for Meniere's disease and other
vestibular disorders (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is
headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol
"EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, investors@aurismedical.com
